Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14253186 | 0.94 | PRKCA (0.49) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL14253452 | 0.90 | PRKCA (0.54) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL4825561 | 0.88 | SCN9A (0.45) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL10283197 | 0.87 | PRKCA (0.45) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL14435398 | 0.87 | SCN9A (0.48) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL5255581 | 0.85 | PRKCA (0.46) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL14253355 | 0.85 | PRKCA (0.53) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL14253483 | 0.85 | SCN9A (0.55) | PRKCAMMP12SCN9ANR1I2 | |
| SCHEMBL14253482 | 0.85 | SCN9A (0.67) | SCN9ANR1I2 | |
| SCHEMBL14253255 | 0.84 | PRKCA (0.48) | PRKCAMMP12SCN9ANR1I2KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1776368-A1 | INHIBITORS OF HCV REPLICATION | Bristol-Myers Squibb Company (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
| WO-2006020082-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | PRKCA 2404/4885MMP12 1013/4885SCN9A 3087/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | PRKCA 2404/4885MMP12 1013/4885SCN9A 3087/4885 |
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | PRKCA 3479/4885MMP12 3512/4885SCN9A 4635/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | PRKCA 3479/4885MMP12 3512/4885SCN9A 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.